BABenedito Albuquerque

Benedito Albuquerque

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benedito Albuquerque has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combined Salmonella and Pasteurella multocida Antigens Single-Dose and Adsorbed in Aluminum Hydroxide–Chitosan Protect Swiss Mice Against Lethal Challenge

    by Hélio S. Brito, Marcela O. Ferreira, Tullio T. Deusdará, Wellington S. Moura, Frederico Eugenio, Gessyk M. Marques, Marcos G. Silva, Edson W. S. Cangussu, Benedito Albuquerque, Gil R. dos Santos, et al.

    Background/Objectives: Avian cholera and typhoid are major bacterial diseases in the poultry industry, causing reduced productivity and economic losses. Here, we developed a single-dose, bivalent, inactivated vaccine. Methods: Different concentrations of the experimental vaccine containing Pasteurella multocida (P. multocida) and Salmonella Gallinarum (S. Gallinarum) antigens adsorbed to an aqueous matrix based on chitosan, aluminum hydroxide, and saponin were evaluated in mice to determine the optimal single-dose concentration. Results: Vaccine efficacy was assessed by survival rates; the experimental vaccine provided complete protection, whereas 67% of animals immunized with a commercial vaccine survived a challenge with 1 × 1010 CFU/mL (2 × 109 CFU/mice) of P. multocida and 5 × 1010 CFU/mL (1 × 1010 CFU/mice) of S. Gallinarum. Subsequently, experiments were conducted to determine the cytokine profiles of animals immunized with the experimental vaccine (single-dose vs. double-dose regimens) followed by a challenge. Pre-challenge cytokine analysis revealed similar profiles for interleukin (IL)-2, IL-4, IL-10, IL-17, interferon gamma (IFN-γ), and Tumor necrosis factor (TNF-α) across groups; however, IL-6 levels were significantly higher in the single-dose experimental vaccine group (G1) than in the commercial vaccine group (G2). In the post-challenge comparative study, the cytokine response induced by the single-dose vaccine was robust and stable, showing no negative interference following the S. Gallinarum challenge, although the double-dose regimen did boost cellular and regulatory cytokines (IFN-γ, TNF-α, and IL-10) specifically against S. Gallinarum. Conversely, no significant differences in cytokine profiles were observed among the treatments for groups challenged with P. multocida or for unchallenged groups. Conclusions: The single-dose regimen proved sufficient to confer complete protective immunity against both pathogens, suggesting it is a promising strategy for simultaneously preventing avian typhoid and cholera.

  • Open Access

    Combined Salmonella and Pasteurella multocida Antigens, Single-Dose and Adsorbed in Aluminum Hydroxide-Chitosan, Protect Swiss Mice Against Lethal Challenge

    by Hélio S. Brito, Marcela O. Ferreira, Tullio T. Deusdará, Wellington S. Moura, Frederico Eugênio, Gessyk M. Marques, Marcos G. Silva, Edson W. S. Cangussu, Benedito Albuquerque, Gil R. dos Santos, et al.

    Avian cholera and typhoid are major bacterial diseases in the poultry industry, causing reduced productivity and economic losses. Here, we developed a single-dose, bivalent, inactivated vaccine containing Pasteurella multocida and Salmonella spp. antigens adsorbed to an aqueous matrix based on chitosan, aluminum hydroxide, and saponin. Different concentrations of the experimental vaccine were evaluated in mice to determine the optimal single-dose concentration. Vaccine efficacy was assessed by survival rates; the experimental vaccine provided complete protection, whereas 60% of animals immunized with a commercial vaccine survived a challenge with 1×10¹⁰ CFU/mL of P. multocida and 5×10¹⁰ CFU/mL of Salmonella spp. Subsequently, experiments were conducted to determine the cytokine profiles of animals immunized with the experimental vaccine (single-dose vs. double-dose regimens) followed by a challenge. Pre-challenge cytokine analysis revealed similar profiles for IL-2, IL-4, IL-10, IL-17, IFN-γ, and TNF-α across groups; however, IL-6 levels were significantly higher in the single-dose experimental vaccine group (G1) than in the commercial vaccine group (G2). In the post-challenge comparative study, the cytokine response induced by the single-dose vaccine was robust and stable, showing no negative interference following the Salmonella spp. challenge, although the double-dose regimen did boost cellular and regulatory cytokines (IFN-γ, TNF-α, and IL-10) specifically against Salmonella spp. Conversely, no significant differences in cytokine profiles were observed among the treatments for groups challenged with P. multocida or for unchallenged groups. The single-dose regimen proved fully sufficient to confer complete protective immunity against both pathogens. The results demonstrated the potential of the single-dose bivalent inactivated vaccine as a promising strategy for the simultaneous prevention of avian typhoid and cholera.

  • Open Access

    Preparation of β-Myrcene-Chitosan Nanoparticles and Their Uptake and Toxicity in Aedes aegypti Larvae

    by Lara T. M. Costa, Bruna L. Rocha, Cleidiane C. Teixeira, Hemilly C. Martins, Mauren Cristine A. Silveira, Benedito Albuquerque, Alex Sander R. Cangussu, Peng He, Raimundo Wagner S. Aguiar, Ana Maria S. Maia, et al.

    Mosquito control still relies heavily on synthetic molecules, which can lead to the selection of resistant populations and undesirable environmental problems. This study described the preparation of a nanoparticle of the plant-derived molecule, β-myrcene, with chitosan, and the assessment of its toxicity against larvae of the yellow fever mosquito, Aedes aegypti. By producing fluorescent chitosan nanoparticles, we were able to observe their distribution in the digestive tract of larvae of Ae. aegypti. Chitosan-based nanoparticles containing β-myrcene (238 mg/L) could kill 100% of the larvae tested, whereas the blank control (i.e., the nanoparticle without β-myrcene) showed no larvicidal activity. The chitosan nanoparticles with β-myrcene had a zeta potential of +15 mV and a hydrodynamic diameter ranging from 30 to 2800 nm. The blank control, without β-myrcene, had a zeta potential of +26 mV and a diameter of 30 to 830 nm. Fluorescence analysis showed that the nanoparticles were efficiently absorbed and distributed in the digestive tract organs of the Ae. aegypti larvae. In short, our results reinforce the benefits of using chitosan to carry molecules of plant-derived-molecules, such as β-myrcene, in mosquito control, suggesting a broad internal distribution that contributes to their toxicity.


  • Open Access

    Using an Aluminum Hydroxide–Chitosan Matrix Increased the Vaccine Potential and Immune Response of Mice against Multi-Drug-Resistant Acinetobacter baumannii

    by Túllio T. Deusdará, Mellanie K. C. Félix, Helio de S. Brito, Edson W. S. Cangussu, Wellington de S. Moura, Benedito Albuquerque, Marcos G. Silva, Gil R. dos Santos, Paula B. de Morais, Elizangela F. da Silva, et al.

    Acinetobacter baumannii is a Gram-negative, immobile, aerobic nosocomial opportunistic coccobacillus that causes pneumonia, septicemia, and urinary tract infections in immunosuppressed patients. There are no commercially available alternative antimicrobials, and multi-drug resistance is an urgent concern that requires emergency measures and new therapeutic strategies. This study evaluated a multi-drug-resistant A. baumannii whole-cell vaccine, inactivated and adsorbed on an aluminum hydroxide–chitosan (mAhC) matrix, in an A. baumannii sepsis model in immunosuppressed mice by cyclophosphamide (CY). CY-treated mice were divided into immunized, non-immunized, and adjuvant-inoculated groups. Three vaccine doses were given at 0D, 14D, and 28D, followed by a lethal dose of 4.0 × 108 CFU/mL of A. baumannii. Immunized CY-treated mice underwent a significant humoral response, with the highest IgG levels and a higher survival rate (85%); this differed from the non-immunized CY-treated mice, none of whom survived (p < 0.001), and from the adjuvant group, with 45% survival (p < 0.05). Histological data revealed the evident expansion of white spleen pulp from immunized CY-treated mice, whereas, in non-immunized and adjuvanted CY-treated mice, there was more significant organ tissue damage. Our results confirmed the proof-of-concept of the immune response and vaccine protection in a sepsis model in CY-treated mice, contributing to the advancement of new alternatives for protection against A. baumannii infections.